Key result
IGFBP-3 regulates cell proliferation and promotes pro-apoptotic effects in cancer cells through both IGF-dependent and IGF-independent signaling pathways.
IGFBP-3 induces apoptosis in cancer cells through both IGF-dependent and IGF-independent signaling pathways.
Supports preclinical rationale for IGFBP-3 modulation in cancer; leaves open translation to clinical practice.
Insulin-like growth factor binding protein-3 (IGFBP-3), a secretory protein, is the most abundant IGF binding protein present in human serum among all IGF binding proteins. IGFBP-3 shows decreased level of expression in cancerous cells but has been known to be present in significant amounts in normal or non-cancerous cells. IGFBP-3 can induce apoptosis in prostate cancer cells either in an IGF-dependent manner or independently of IGF binding. Although putative cell death specific Insulin-like growth factor binding protein-3 (IGFBP-3R) receptor(s) has recently been identified by which IGFBP-3 may induce its anti-tumor effects, IGFBP-3 has also been known to activate various downstream intracellular signaling molecules via a different mechanistic pathway. Stat-1 has been known to be one of the candidate molecules activated by IGFBP-3. IGFBP-3 can also inhibit Akt/IGF-1 survival pathway in MCF- 7 breast cancer cells which ultimately leads to the induction of apoptosis in these cells. All these studies clearly demonstrate that IGFBP-3 regulates cell proliferation and promotes its pro-apoptotic effects in cancer cells in two different pathways,1) sequester IGF-I to bind to IGF-I receptor to inhibit cell proliferation and induce apoptosis, 2) independent of IGF-I pathway, IGFBP-3 binds to some putative receptor and activate various downstream pro-apoptotic molecules involved in cell death.
No takes yet. Share an insight, caveat, or question.
Shahjee et al. (2014) conducted a review in Cancer. IGFBP-3 was evaluated on Apoptosis and cell proliferation. IGFBP-3 regulates cell proliferation and promotes pro-apoptotic effects in cancer cells through both IGF-dependent and IGF-independent signaling pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: